Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tift Mann

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
JACC. Cardiovascular Interventions|May 26, 2009
TAXUS Liberté attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS programEhtisham Mahmud, John A Ormiston, Mark A Turco, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|December 7, 2010
Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Liberté vs. TAXUS Express: the importance of stent platform design for drug-eluting stentsNeil J Weissman, Mark A Turco, John A Ormiston, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS programMark A Turco, John A Ormiston, Jeffrey J Popma, et al.
Journal of the American College of Cardiology|July 4, 2006
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trialDuane S Pinto, Gregg W Stone, Stephen G Ellis, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 19, 2011
A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trialLouis A Cannon, Dean J Kereiakes, Tift Mann, et al.
Journal of the American College of Cardiology|April 20, 2005
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trialNeil J Weissman, Joerg Koglin, David A Cox, et al.
Journal of the American College of Cardiology|April 24, 2007
Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trialMark A Turco, John A Ormiston, Jeffrey J Popma, et al.
Journal of the American College of Cardiology|September 19, 2003
A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) StudyDavid J Moliterno, James B Hermiller, Dean J Kereiakes, et al.
The American Journal of Cardiology|April 28, 2004
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)A Michael Lincoff, John A Bittl, Neal S Kleiman, et al.
International Journal of Cardiology|June 11, 2011
A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trialWilliam A Gray, Alan C Yeung, Donald E Cutlip, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
JACC. Cardiovascular Interventions|May 26, 2009
TAXUS Liberté attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS programEhtisham Mahmud, John A Ormiston, Mark A Turco, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|December 7, 2010
Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Liberté vs. TAXUS Express: the importance of stent platform design for drug-eluting stentsNeil J Weissman, Mark A Turco, John A Ormiston, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS programMark A Turco, John A Ormiston, Jeffrey J Popma, et al.
Journal of the American College of Cardiology|July 4, 2006
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trialDuane S Pinto, Gregg W Stone, Stephen G Ellis, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 19, 2011
A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trialLouis A Cannon, Dean J Kereiakes, Tift Mann, et al.
Journal of the American College of Cardiology|April 20, 2005
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trialNeil J Weissman, Joerg Koglin, David A Cox, et al.
Journal of the American College of Cardiology|April 24, 2007
Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trialMark A Turco, John A Ormiston, Jeffrey J Popma, et al.
Journal of the American College of Cardiology|September 19, 2003
A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) StudyDavid J Moliterno, James B Hermiller, Dean J Kereiakes, et al.
The American Journal of Cardiology|April 28, 2004
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)A Michael Lincoff, John A Bittl, Neal S Kleiman, et al.
International Journal of Cardiology|June 11, 2011
A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trialWilliam A Gray, Alan C Yeung, Donald E Cutlip, et al.
Pageof 5